These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 32975600)
1. Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in France. Loffroy R; Ronot M; Greget M; Bouvier A; Mastier C; Sengel C; Tselikas L; Arnold D; Maleux G; Pelage JP; Pellerin O; Peynircioglu B; Sangro B; Schaefer N; Urdániz M; Kaufmann N; Bilbao JI; Helmberger T; Vilgrain V; Cardiovasc Intervent Radiol; 2021 Jan; 44(1):36-49. PubMed ID: 32975600 [TBL] [Abstract][Full Text] [Related]
2. Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT). Helmberger T; Golfieri R; Pech M; Pfammatter T; Arnold D; Cianni R; Maleux G; Munneke G; Pellerin O; Peynircioglu B; Sangro B; Schaefer N; de Jong N; Bilbao JI; ; Cardiovasc Intervent Radiol; 2021 Jan; 44(1):21-35. PubMed ID: 32959085 [TBL] [Abstract][Full Text] [Related]
3. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life. Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814 [TBL] [Abstract][Full Text] [Related]
4. Predictive Factors for Adverse Event Outcomes After Transarterial Radioembolization with Yttrium-90 Resin Microspheres in Europe: Results from the Prospective Observational CIRT Study. Maleux G; Albrecht T; Arnold D; Bargellini I; Cianni R; Helmberger T; Kolligs F; Munneke G; Peynircioglu B; Sangro B; Schaefer N; Pereira H; Zeka B; de Jong N; Bilbao JI; Cardiovasc Intervent Radiol; 2023 Jul; 46(7):852-867. PubMed ID: 36914788 [TBL] [Abstract][Full Text] [Related]
5. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study. Kolligs F; Arnold D; Golfieri R; Pech M; Peynircioglu B; Pfammatter T; Ronot M; Sangro B; Schaefer N; Maleux G; Munneke G; Pereira H; Zeka B; de Jong N; Helmberger T; JHEP Rep; 2023 Feb; 5(2):100633. PubMed ID: 36593888 [TBL] [Abstract][Full Text] [Related]
6. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres. Wang EA; Stein JP; Bellavia RJ; Broadwell SR Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319 [TBL] [Abstract][Full Text] [Related]
7. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342 [TBL] [Abstract][Full Text] [Related]
8. Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma. Kirchner T; Marquardt S; Werncke T; Kirstein MM; Brunkhorst T; Wacker F; Vogel A; Rodt T Abdom Radiol (NY); 2019 Apr; 44(4):1554-1561. PubMed ID: 30311050 [TBL] [Abstract][Full Text] [Related]
9. Factors Impacting Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Combined Analysis of the Prospective CIRT Studies. Reimer P; Vilgrain V; Arnold D; Balli T; Golfieri R; Loffroy R; Mosconi C; Ronot M; Sengel C; Schaefer N; Maleux G; Munneke G; Peynircioglu B; Sangro B; Kaufmann N; Urdaniz M; Pereira H; de Jong N; Helmberger T Cardiovasc Intervent Radiol; 2024 Mar; 47(3):310-324. PubMed ID: 38321223 [TBL] [Abstract][Full Text] [Related]
10. Effect of Yttrium-90 transarterial radioembolization in patients with non-surgical hepatocellular carcinoma: A systematic review and meta-analysis. Lemieux S; Buies A; F Turgeon A; Hallet J; Daigle G; Côté F; Provencher S PLoS One; 2021; 16(3):e0247958. PubMed ID: 33662011 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S; J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371 [TBL] [Abstract][Full Text] [Related]
12. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma. Kallini JR; Gabr A; Salem R; Lewandowski RJ Adv Ther; 2016 May; 33(5):699-714. PubMed ID: 27039186 [TBL] [Abstract][Full Text] [Related]
13. Evaluating the Effectiveness of Yttrium-90 Glass Microspheres in the Treatment of Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, and Metastatic Colorectal Cancer in Practice: Protocol for the Prospective PROACTIF Phase IV Registry Study in France. Garin E; Pinaquy JB; Bailly C; Sengel C; Mariano-Goulart D; Edeline J; Blanc JF; Bouvier A; Tordo J; Rode A; Becker S; Sefrioui D; de Baere T; Somma C; Mastier C; Goupil J; Chevallier P; Regnault H; Vibert E; Manfredi S; Vicaut E; Patel B; Boucher E; Guiu B; Cardiovasc Intervent Radiol; 2022 Jan; 45(1):1-11. PubMed ID: 34796373 [TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study. Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511 [TBL] [Abstract][Full Text] [Related]
15. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G; Trials; 2014 Dec; 15():474. PubMed ID: 25472660 [TBL] [Abstract][Full Text] [Related]
16. Transarterial Radioembolization Treatment as a Bridge to Surgical Resection in Pediatric Hepatocellular Carcinoma. Whitlock RS; Loo C; Patel K; Bista R; Goss JA; Heczey A; Khan O; Lopez-Terrada D; Masand P; Nguyen H; Mahvash A; Vasudevan SA; Kukreja K J Pediatr Hematol Oncol; 2021 Nov; 43(8):e1181-e1185. PubMed ID: 33769387 [TBL] [Abstract][Full Text] [Related]
18. Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma. Kim Y; Lee HA; Lee JS; Jeon MY; Kim BK; Park JY; Kim DY; Ahn SH; Um SH; Seo YS; Kim SU Cancer Invest; 2021 Mar; 39(3):274-283. PubMed ID: 33356630 [TBL] [Abstract][Full Text] [Related]
19. Survival and Toxicities after Emmons EC; Bishay S; Du L; Krebs H; Gandhi RT; Collins ZS; O'Hara R; Akhter NM; Wang EA; Grilli C; Brower JS; Peck SR; Petroziello M; Abdel Aal AK; Golzarian J; Kennedy AS; Matsuoka L; Sze DY; Brown DB Radiology; 2022 Oct; 305(1):228-236. PubMed ID: 35762890 [TBL] [Abstract][Full Text] [Related]
20. Transarterial chemoembolization and yittrium-90 for liver cancer and other lesions. Minocha J; Salem R; Lewandowski RJ Clin Liver Dis; 2014 Nov; 18(4):877-90. PubMed ID: 25438288 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]